Skip to main content
Quest PharmaTech Inc. logo

Quest PharmaTech Inc. - Investor Relations & Filings

Listed IPO Jul 1997
Ticker · QPT ISIN · CA74836M1068 TSXV Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2023-06-29 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV QPT · 4 venues

Key figures FY2024

Period ended 2024-01-31 · CAD
Headline annual figures for Quest PharmaTech Inc., fiscal year 2024, reported in CAD, with the source filing for each figure.
Net Income CAD -3.02M per the Annual Report filed 2024-05-29
Total Assets CAD 24.48M per the Annual Report filed 2024-05-29
Total Equity CAD 23.15M per the Annual Report filed 2024-05-29
Cash from Ops CAD -342.42k per the Annual Report filed 2024-05-29

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Quest PharmaTech Inc.

https://questpharmatech.com/

Quest PharmaTech Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics. The company's pipeline targets applications in cancer treatment, dermatology, and wound healing, utilizing both proprietary technologies, such as transdermal delivery systems, and strategic investments. A core proprietary asset is the antibody Mab AR 9.6, licensed for targeted cancer therapy against truncated O-glycan on MUC16. Quest also maintains significant ownership interests in associated entities, including OncoVent, and holds convertible bond interests in OncoQuest Pharmaceuticals, Inc. (OQP). These OQP bonds are planned to be exchanged into shares of Canaria Bio, a company developing immunotherapy assets, providing Quest with an expected ownership stake of approximately 23% in Canaria Bio upon conversion.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements (Unaudited)' for the three months ended April 30, 2023 and 2022. It contains detailed financial statements including statements of financial position, loss and comprehensive loss, changes in shareholders' equity, cash flows, and notes to the financial statements. The period covered is a quarter (three months), and the document is unaudited, consistent with interim or quarterly reporting. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-06-29 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Voting Instruction Form' (VIF) for an Annual General Meeting. It provides instructions for shareholders to vote on matters such as the election of directors and the appointment of auditors. This type of document is a standard proxy solicitation material sent to shareholders to request their votes for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2023-06-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a corporate update announcing the grant of stock options to officers. It does not contain financial statements, detailed financial performance, or comprehensive report data. The length is short (1796 characters), and it is an announcement of a corporate event related to stock options. This fits best under Capital/Financing Update (CAP) as it relates to company financing activities (stock options granted).
2023-06-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release issued by Quest PharmaTech Inc. to clarify details regarding a previously announced non-binding agreement in principle. It discusses potential monetization of bonds and merger activities, which are corporate developments. Since it does not fit into specific categories like M&A (which usually refers to definitive agreements or formal takeover bids) or other financial reporting categories, and serves as a general regulatory disclosure/clarification requested by the TSX Venture Exchange, it falls under the RNS (Regulatory Filings) category.
2023-06-06 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a corporate update press release from Quest PharmaTech Inc. It discusses a non-binding agreement in principle regarding convertible debentures and cash proceeds, completion of annual filings including audited financial statements and MD&A for the year ending January 31, 2023, and announces the date and details of the upcoming annual general meeting. The document does not contain the full annual report or financial statements but references that these have been filed and are available on SEDAR. It also includes forward-looking statements and general corporate information. The primary content is an update on financing-related transactions and corporate events rather than a full financial report or detailed management discussion. Given the focus on financing transactions and corporate updates, and the absence of detailed financial statements or earnings data, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-02 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. It is a FORM 52-109FV2 Venture Issuer Basic Certificate, which is a certification of interim filings. The document does not contain actual financial data or substantive financial analysis but rather attests to the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2954 characters), and it is primarily a certification letter, not the report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2023-05-31 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.